Yenealem Temesgen‐Oyelakin

Author

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Also Known As

Y Temesgen-Oyelakin, Yenealem Temesgen-Oyelakin, Yenealem Temesgen‐Oyelakin

Publications

502

Citations

H-Index

Concepts

All Affiliations

National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health National Heart Lung and Blood Institute National Institutes of Health Clinical Center Carolina Arthritis Associates

About

Yenealem Temesgen‐Oyelakin is an author at National Institute of Arthritis and Musculoskeletal and Skin Diseases specializing in systemic lupus erythematosus, clinical trials, and systemic lupus erythematosus treatment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	13
2	Immunology	1	1	13
3	Pharmacology	1	1	13
4	Rheumatology	1	1	13
5	Autoimmune Disease	1	1	13

Yenealem Temesgen‐Oyelakin

Publications

496

Citations

H-Index

Page 1

	Year	Citations
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis, Nature Communications	2021	182
Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus Philip M. Carlucci, Monica Purmalek, Amit K. Dey, JCI Insight	2018	179
Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis, Arthritis & Rheumatology	2018	62
Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE Monica Purmalek, Philip M. Carlucci, Amit K. Dey, Lupus Science & Medicine	2019	25
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus Sarfaraz Hasni, Yenealem Temesgen‐Oyelakin, Michael A. Davis, Annals of the Rheumatic Diseases	2022	24
183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis, Abstracts ImmunologyPharmacotherapyImmune DysregulationInflammationClinical Trials	2019	13
The Aconitate Decarboxylase 1/Itaconate Pathway Modulates Immune Dysregulation and Associates with Cardiovascular Disease Markers and Disease Activity in Systemic Lupus Erythematosus Eduardo Patiño‐Martínez, Shuichiro Nakabo, Kan Jiang, The Journal of Immunology	2024	11

Page 1